Drug intelligence / Profile preview

methosulide

Development stage: Phase 1
Lead developer: Academy of Military Medical Sciences
Modality: Small Molecules
Administration: Oral

Overview

Methosulide is a nonsteroidal anti-inflammatory drug (NSAID) developed by the Academy of Military Medical Sciences in collaboration with People's Medical Group. It acts primarily as a selective cyclooxygenase-2 (COX-2) inhibitor, reducing the synthesis of inflammatory mediators such as prostaglandins (PGI1, PGE1, PGE2) and thromboxane A2 (TXA2). This mechanism provides antipyretic, analgesic, anti-inflammatory, and anti-edema effects. Methosulide has been studied for its pharmacokinetics and safety in oral film-coated tablet form but is insoluble in water and currently lacks widely available formulations. Its development aims to achieve good efficacy with high bioavailability and minimal side effects.[3][8]

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on methosulide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methosulide.

Explore the full profile